Suppr超能文献

定坤丹对比妈富隆治疗原发性痛经的疗效:一项前瞻性、双盲、多中心、随机对照研究。

The effect of Ding-kun-dan comparing with Marvelon on primary dysmenorrhea: A prospective, double-blind, multicenter, randomized controlled trial.

机构信息

National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeAddress: Peking Union Medical College Hospital (East), No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

出版信息

J Ethnopharmacol. 2024 Jan 10;318(Pt B):116975. doi: 10.1016/j.jep.2023.116975. Epub 2023 Jul 29.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Ding-kun-dan (DKD), as one of well-known traditional Chinese medicine (TCM), is considered as an effective prescription to regulate menstruation, benefit Qi and nourish the blood. Previous studies had showed that DKD could improve sex hormone levels, insulin resistance, metabolism abnormalities and regulate immunity in animal models with polycystic ovary syndrome or endometriosis, however, little study conducted to reveal its clinical efficacy in Primary Dysmenorrhea (PD).

AIM OF THE STUDY

To compare the effect of Ding-kun-dan (DKD) with Marvelon on relief of symptoms and change of serum pain-related factors in patients with primary dysmenorrhea.

MATERIALS AND METHOD

136 patients with primary dysmenorrhea were randomly assigned to the DKD group (n = 73, take one tablet per day from 5th day of the menstrual cycle for 10 days every 28 days) and the Marvelon group (n = 63, take one tablet per day from 5th day of the menstrual cycle for 21 days every 28 days), the therapeutic effects were analyzed through evaluating the change of VAS scores, CMSS scores and the level of PGF, PGE, PGF/PGE and NO during the 12 weeks intervention.

RESULTS

Both DKD and Marvelon could effectively relief pain and other associated symptoms at each visit (Baseline, 4 week, 8 week and 12 week). Although Marvelon was significantly superior to DKD in reducing VAS scores, the total CMSS, CMSS severity and duration scores at each posttreatment follow-up (P < 0.01), VAS scores in the DKD group decreased significantly over time while scores in the COC group only dropped rapidly after the first two months of treatment. Efficacy gap between two interventions continuously narrowed over time and the efficacy of DKD became non-inferior at the 12 week compared to that of Marvelon (the difference between groups, - 0.78%; 95% confidence interval (CI), -13.67%-12.75%; non-inferiority margin, 15%). DKD group had better efficacy on mild pain compared to that of the COC group with no statistical difference (75% VS 61.9%, P > 0.05). DKD and Marvelon could effectively reduce PGF, PGE and higher PGF/PGE in patients with PD. There was no statistical difference in the level of PGF, PGE, PGF/PGE and NO between DKD and Marvelon group at each follow-up. No serious adverse effect was observed.

CONCLUSION

Ding-kun-dan is another available, effective and safe method for patients with primary dysmenorrhea to choose, especially for those who are suffered from mild pain and/or contraindicated to hormonal agents.

摘要

民族药理学相关性

定坤丹(DKD)作为一种著名的中药(TCM),被认为是一种调节月经、益气养血的有效处方。先前的研究表明,DKD 可以改善多囊卵巢综合征或子宫内膜异位症动物模型中的性激素水平、胰岛素抵抗、代谢异常和调节免疫,但很少有研究表明其在原发性痛经(PD)中的临床疗效。

研究目的

比较定坤丹(DKD)与妈富隆对原发性痛经患者症状缓解及血清疼痛相关因子变化的影响。

材料与方法

将 136 例原发性痛经患者随机分为 DKD 组(n=73,从月经周期第 5 天开始每天服用 1 片,每 28 天服用 10 天)和妈富隆组(n=63,从月经周期第 5 天开始每天服用 1 片,每 28 天服用 21 天),通过评估 VAS 评分、CMSS 评分和 12 周干预期间 PGF、PGE、PGF/PGE 和 NO 水平的变化来分析治疗效果。

结果

DKD 和妈富隆在每次就诊时(基线、4 周、8 周和 12 周)均能有效缓解疼痛及其他相关症状。虽然妈富隆在降低 VAS 评分方面明显优于 DKD,但在每次治疗后随访的总 CMSS、CMSS 严重程度和持续时间评分(P<0.01),DKD 组的 VAS 评分随时间显著下降,而 COC 组的评分仅在治疗后前两个月迅速下降。两种干预措施的疗效差距随时间不断缩小,DKD 在 12 周时的疗效与妈富隆非劣效(组间差异,-0.78%;95%置信区间(CI),-13.67%~12.75%;非劣效性边界,15%)。与 COC 组相比,DKD 组对轻度疼痛的疗效更好,但差异无统计学意义(75%比 61.9%,P>0.05)。DKD 和妈富隆均可有效降低 PD 患者的 PGF、PGE 和更高的 PGF/PGE。在每次随访时,DKD 组和妈富隆组之间 PGF、PGE、PGF/PGE 和 NO 的水平均无统计学差异。未观察到严重不良事件。

结论

定坤丹是原发性痛经患者另一种有效且安全的选择方法,特别是对于那些患有轻度疼痛和/或对激素药物禁忌的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验